epstein-barr-virus

Documents about epstein-barr-virus

• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)#674906ClinicalTrials.gov
• Genetic Studies of Chronic Active Epstein-Barr Disease#1451251ClinicalTrials.gov
• Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations#867536ClinicalTrials.gov
• Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents#832640ClinicalTrials.gov
• Immunodeficiency for Severe Epstein-Barr Virus Infection#1057595ClinicalTrials.gov
• Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome#1045791ClinicalTrials.gov
• Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies#1032857ClinicalTrials.gov
• Epstein-Barr virus reprograms immune escape in nasopharyngeal carcinoma#253493Europe PMC
• L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis#806627ClinicalTrials.gov
• Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection#1197870ClinicalTrials.gov
• Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening#1463951ClinicalTrials.gov
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults#369868ClinicalTrials.gov
• Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies#332743ClinicalTrials.gov
• EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients#1349202ClinicalTrials.gov
• Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma#915950ClinicalTrials.gov
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas#844338ClinicalTrials.gov
• Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma#1321338ClinicalTrials.gov
• Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL#881288ClinicalTrials.gov
• L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH#909468ClinicalTrials.gov
• Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma#1007724ClinicalTrials.gov
• Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia#1151802ClinicalTrials.gov
• Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders#1213802ClinicalTrials.gov
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy#871373ClinicalTrials.gov
• Prevalence of Epstein-Barr Virus Infection#1433183ClinicalTrials.gov
• The case for an Epstein-Barr virus vaccine: Lessons from its link to systemic lupus erythematosus#120197Europe PMC
• Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy#909211ClinicalTrials.gov
• Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma#835020ClinicalTrials.gov
• mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults#238192ClinicalTrials.gov
• Functional determinants of the Epstein-Barr virus protease#1500782HAL (France)
• Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)#804034ClinicalTrials.gov
• TGFβ links EBV to multisystem inflammatory syndrome in children#465751Repositorio Universidad del Desarrollo
• Human genetic and immunological determinants of Epstein–Barr virus-driven disease#250257HAL (France)
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer#279520ClinicalTrials.gov
• Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)#906216ClinicalTrials.gov
• Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)#1140763ClinicalTrials.gov
• Modified Vaccinia Ankara (MVA) Vaccine Study#325157ClinicalTrials.gov
• Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes#377407ClinicalTrials.gov
• Tabes Dorsalis With Spinal Meningeal Involvement and Possible Concomitant Epstein-Barr Virus Reactivation.#440875NCBI PubMed Central
• Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons#826321ClinicalTrials.gov
• Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors#325289ClinicalTrials.gov
• Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes#1308454ClinicalTrials.gov
• Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma#1432200ClinicalTrials.gov
• A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion#31430HAL (France)
• Network analysis of Mycoplasma pneumoniae pneumonia and Epstein-Barr virus co-infection.#220989NCBI PubMed Central
• Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency#643248HAL (France)
• Supporting data for "A Multi-omics Study Reveals an Epigenomic Subtype Shapes a Pro-metastatic Niche in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma"#387536Figshare
• Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection#1196710ClinicalTrials.gov
• Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients#1443523ClinicalTrials.gov
• Epstein–Barr virus‐encoded EBNA1 and ZEBRA : targets for therapeutic strategies against EBV ‐carrying cancers#31432HAL (France)
• Dynamic early biomarkers predict outcomes in pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.#469133NCBI PubMed Central